Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

• Główni autorzy: Alexander Egeberg (Autor), Jason E. Hawkes (Autor), Najwa Somani (Autor), Russel Burge (Autor), Kyoungah See (Autor), Gaia Gallo (Autor), Missy McKean-Matthews (Autor), Melinda Gooderham (Autor), George Han (Autor), April Armstrong (Autor)
• Format: Książka
• Wydane: Adis, Springer Healthcare, 2024-04-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat with non-systemic therapies, this post hoc analysis f...